Drug intelligence / Profile preview

Envarsus XR + azathioprine

Development stage: Unknown
Lead developer: Veloxis Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Envarsus XR + azathioprine is a once-daily immunosuppressive regimen being evaluated by the Washington University School of Medicine for use in kidney transplant recipients. This combination consists of Envarsus XR, an extended-release formulation of the calcineurin inhibitor tacrolimus, and azathioprine, a purine synthesis inhibitor. The regimen is designed to improve patient compliance and tolerability compared to standard twice-daily regimens (such as immediate-release tacrolimus combined with mycophenolic acid) while maintaining efficacy in preventing biopsy-proven organ rejection. Envarsus XR utilizes MeltDose technology to enhance bioavailability and allow for once-daily dosing with a smoother pharmacokinetic profile and reduced peak-to-trough fluctuations compared to immediate-release tacrolimus formulations.

Brand names: Envarsus XRImuranAzasan
Other names: LCP-tacrolimus + azathioprineLCPT + azathioprineOnce-daily tacrolimus + azathioprineextended-release tacrolimus + azathioprine

Targets

RAC1 (Rac family small GTPase 1)CN (Calcineurin)

Beyond the preview

Go deeper on Envarsus XR + azathioprine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Envarsus XR + azathioprine.

Explore the full profile